Investigating the Mechanisms Regulating RORgamma Activity
研究调节 RORgamma 活性的机制
基本信息
- 批准号:8386607
- 负责人:
- 金额:$ 1.99万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-12-01 至 2013-03-31
- 项目状态:已结题
- 来源:
- 关键词:7-ketocholesterolAffinityAgonistAutoimmune DiseasesBindingCarbohydratesCell physiologyCellsCircadian RhythmsDevelopmentDiseaseHepatocyteHumanHydroxycholesterolsIn VitroLigandsLipidsLiverMalignant NeoplasmsMediatingMetabolic DiseasesMetabolic PathwayMetabolic syndromeMorbidity - disease rateMusNuclear Hormone ReceptorsNuclear Orphan ReceptorObesityOrphanOsteoporosisPathologyPharmacologic SubstancePhysiologicalPhysiological ProcessesPlayProcessProteinsPublishingRORA geneRetinoic Acid ReceptorRoleSpecificitySterolsTestingWorkbasecell typecofactorglucose metabolismin vivolipid metabolismmortalitymouse modelnew therapeutic targetpublic health relevancereceptor
项目摘要
DESCRIPTION (provided by applicant): Metabolic diseases, associated with abnormal processing of proteins, carbohydrates, and lipids, are the cause of significant morbidity and mortality. The orphan nuclear receptors, retinoic acid receptor-related orphan receptors 1, -2, and -3 (ROR1, ROR2, and ROR3), play important roles in regulating glucose and lipid metabolism, circadian rhythm, and have been implicated in the pathology of several diseases, including osteoporosis, autoimmune diseases, cancer, and obesity. Detailed examination of mice deficient in ROR1 has revealed a significant amount of information regarding its role in regulating metabolic pathways, including lipid metabolism. ROR3 has been extensively evaluated in regards to its essential role in Th17 cell development and association with certain autoimmune diseases. However, little is known about ROR3's role in other cell types or its mechanism of action. We have identified endogenous, functional ligands (7- oxygenated sterols) for ROR3. Additionally, we recently published that the benzenesulfoamide liver X receptor (LXR) agonist T0901317 is also a high affinity synthetic ligand for ROR3. 7-oxygenated sterols (71-hydroxycholesterol, 72- hydroxycholesterol, and 7-ketocholesterol) play important physiological and pathological roles in humans. The long-term objective is to determine the role of these ligands in regulating the activity of ROR3. We hypothesize that 7-oxygenated sterols are key ligands that regulate ROR3 mediated cellular processes. Our hypothesis will be tested in the following specific aims: Specific Aim 1 will determine the specificity of ROR3 for various sterols; Specific Aim 2 will determine the specificity of synthetic ligands on ROR3; and in Specific Aim 3 we will determine the effects of natural and synthetic ligands on ROR3 regulated physiological processes. These studies are essential for our understanding of how ligands may coordinate ROR3 regulated functions. Ligand-regulated nuclear hormone receptors have been definitively shown to be effective targets for the development of pharmaceuticals. We predict that these studies will provide the basis for novel therapeutics targeting ROR3 for the treatment of metabolic disorders.
描述(由申请方提供):与蛋白质、碳水化合物和脂质的异常加工相关的代谢性疾病是显著发病率和死亡率的原因。孤儿核受体,视黄酸受体相关孤儿受体1、-2和-3(ROR 1、ROR 2和ROR 3),在调节葡萄糖和脂质代谢、昼夜节律中起重要作用,并且已经涉及几种疾病的病理学,包括骨质疏松症、自身免疫性疾病、癌症和肥胖症。对ROR 1缺陷小鼠的详细检查揭示了关于其在调节代谢途径(包括脂质代谢)中的作用的大量信息。ROR 3在Th 17细胞发育中的重要作用以及与某些自身免疫性疾病的相关性方面已被广泛评估。然而,关于ROR 3在其他细胞类型中的作用或其作用机制知之甚少。我们已经鉴定了ROR 3的内源性功能性配体(7-含氧固醇)。此外,我们最近发表了苯磺酰胺肝X受体(LXR)激动剂T0901317也是ROR 3的高亲和力合成配体。7-含氧甾醇(71-羟基胆固醇、72-羟基胆固醇和7-酮胆固醇)在人体中起重要的生理和病理作用。长期目标是确定这些配体在调节ROR 3活性中的作用。我们假设7-氧合甾醇是调节ROR 3介导的细胞过程的关键配体。我们的假设将在以下具体目标中进行测试:具体目标1将确定ROR 3对各种甾醇的特异性;具体目标2将确定合成配体对ROR 3的特异性;在具体目标3中,我们将确定天然和合成配体对ROR 3调节的生理过程的影响。这些研究对于我们理解配体如何协调ROR 3调节功能至关重要。配体调节的核激素受体已被明确证明是药物开发的有效靶点。我们预测,这些研究将为靶向ROR 3治疗代谢紊乱的新疗法提供基础。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Laura A Solt其他文献
Laura A Solt的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Laura A Solt', 18)}}的其他基金
Ligand-dependent regulation of the nuclear receptor REV-ERBa in TH17 cell development and inflammation
TH17 细胞发育和炎症中核受体 REV-ERBa 的配体依赖性调节
- 批准号:
10608664 - 财政年份:2023
- 资助金额:
$ 1.99万 - 项目类别:
Identification of cellular heme transport receptors that regulate T cell function
调节 T 细胞功能的细胞血红素转运受体的鉴定
- 批准号:
10666680 - 财政年份:2022
- 资助金额:
$ 1.99万 - 项目类别:
Identification of cellular heme transport receptors that regulate T cell function
调节 T 细胞功能的细胞血红素转运受体的鉴定
- 批准号:
10539212 - 财政年份:2022
- 资助金额:
$ 1.99万 - 项目类别:
Identification of REV-ERB inverse agonists for cancer immunotherapy
用于癌症免疫治疗的 REV-ERB 反向激动剂的鉴定
- 批准号:
10401264 - 财政年份:2019
- 资助金额:
$ 1.99万 - 项目类别:
Regulation of TH17 cell development and function by the REV-ERBs
REV-ERB 对 TH17 细胞发育和功能的调节
- 批准号:
9107618 - 财政年份:2015
- 资助金额:
$ 1.99万 - 项目类别:
Regulation of TH17 Cell Development and Function by the REV-ERBs
REV-ERB 对 TH17 细胞发育和功能的调节
- 批准号:
9187414 - 财政年份:2015
- 资助金额:
$ 1.99万 - 项目类别:
Investigating the Mechanisms Regulating RORgamma Activity
研究调节 RORgamma 活性的机制
- 批准号:
8205652 - 财政年份:2010
- 资助金额:
$ 1.99万 - 项目类别:
Investigating the Mechanisms Regulating RORgamma Activity
研究调节 RORgamma 活性的机制
- 批准号:
8058573 - 财政年份:2010
- 资助金额:
$ 1.99万 - 项目类别:
相似海外基金
Discovery of a High Affinity, Selective and β-arrestin Biased 5-HT7R Agonist
发现高亲和力、选择性和β-抑制蛋白偏向的 5-HT7R 激动剂
- 批准号:
10412227 - 财政年份:2022
- 资助金额:
$ 1.99万 - 项目类别:
Discovery of a High Affinity, Selective and β-arrestin Biased 5-HT7R Agonist
发现高亲和力、选择性和β-抑制蛋白偏向的 5-HT7R 激动剂
- 批准号:
10610473 - 财政年份:2022
- 资助金额:
$ 1.99万 - 项目类别:
Supplement to Discovery of a high affinity, selective and beta-arrestinbiased 5-HT7R Agonist Grant
对高亲和力、选择性和 β 抑制偏向 5-HT7R 激动剂发现的补充补助金
- 批准号:
10799162 - 财政年份:2022
- 资助金额:
$ 1.99万 - 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
- 批准号:
6639179 - 财政年份:2001
- 资助金额:
$ 1.99万 - 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
- 批准号:
6724797 - 财政年份:2001
- 资助金额:
$ 1.99万 - 项目类别:
General Anesthetics and nAcCHOR Agonist Affinity
全身麻醉药和 nAcCHOR 激动剂亲和力
- 批准号:
6636512 - 财政年份:2001
- 资助金额:
$ 1.99万 - 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
- 批准号:
6266928 - 财政年份:2001
- 资助金额:
$ 1.99万 - 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
- 批准号:
6539099 - 财政年份:2001
- 资助金额:
$ 1.99万 - 项目类别:
General Anesthetics and nAcCHOR Agonist Affinity
全身麻醉药和 nAcCHOR 激动剂亲和力
- 批准号:
6326889 - 财政年份:2001
- 资助金额:
$ 1.99万 - 项目类别:
General Anesthetics and nAcCHOR Agonist Affinity
全身麻醉药和 nAcCHOR 激动剂亲和力
- 批准号:
6520329 - 财政年份:2001
- 资助金额:
$ 1.99万 - 项目类别: